Business Context and Reporting Period
This Form 8-K was filed by TriSalus Life Sciences, Inc. on February 18, 2025. The report details the closing of the Second Tranche of a senior secured credit facility previously established with OrbiMed Royalty & Credit Opportunities IV, LP.
Key Financial Metrics and Capital Structure
- Debt Financing: The Company received $10 million in principal from the Second Tranche of its Loan Facility.
- Debt Maturity: The Second Tranche loan matures on April 30, 2029.
- Remaining Capacity: Up to $15 million remains available under the Third Tranche, subject to revenue requirements and a borrowing deadline of December 31, 2025.
- Equity Issuance: The Company issued warrants to purchase an aggregate of 91,263 shares of common stock.
- Warrant Terms: Exercise price of $5.4787 per share with a 7-year term.
Material Changes
The primary material change is the activation of the Second Tranche, increasing the total borrowed amount under the Credit Agreement to $35 million ($25 million from the Initial Closing Date plus $10 million from this closing). Additionally, the Company's capital structure was altered by the issuance of unregistered warrants to the lender.
Outlook, Risks, and Contingencies
- Future Borrowing Conditions: Access to the remaining $15 million Third Tranche is contingent upon the Company satisfying specific revenue requirements.
- Regulatory Status: The warrants and underlying shares were issued under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D. They are unregistered and cannot be offered or sold in the U.S. absent registration or an exemption.
- Warrant Provisions: The warrants include customary participation rights and share/price-based adjustment provisions.
Investor Verification Checklist
- Verify the specific revenue thresholds required to access the remaining $15 million Third Tranche.
- Confirm the total outstanding debt balance and interest rate terms associated with the $35 million drawn facility.
- Review the impact of the 91,263 new warrants on potential future dilution.
- Check for any subsequent filings regarding the registration of the warrant shares.